[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA46022A - Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers - Google Patents

Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers

Info

Publication number
MA46022A
MA46022A MA046022A MA46022A MA46022A MA 46022 A MA46022 A MA 46022A MA 046022 A MA046022 A MA 046022A MA 46022 A MA46022 A MA 46022A MA 46022 A MA46022 A MA 46022A
Authority
MA
Morocco
Prior art keywords
peptides
combination
present
cancers
prostate cancer
Prior art date
Application number
MA046022A
Other languages
English (en)
Other versions
MA46022B1 (fr
Inventor
Jens Fritsche
Valentina Goldfinger
Julia Leibold
Andrea Mahr
Phillip Müller
Oliver Schoor
Harpreet Singh
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA46022A publication Critical patent/MA46022A/fr
Publication of MA46022B1 publication Critical patent/MA46022B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)

Abstract

La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules à utiliser dans des procédés immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie de cancer. La présente invention concerne en outre des épitopes de peptides de lymphocytes t associés à une tumeur, seuls ou en combinaison avec d'autres peptides associés à une tumeur, qui peuvent par exemple servir de principes pharmaceutiques actifs de compositions de vaccin qui stimulent des réponses immunitaires antitumorales, ou stimuler des lymphocytes t ex vivo et les transférer aux patients. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou des peptides tels quels, peuvent également être des cibles d'anticorps, des récepteurs de lymphocytes t solubles, et d'autres molécules de liaison.
MA46022A 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers MA46022B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201289P 2015-08-05 2015-08-05
GBGB1513921.5A GB201513921D0 (en) 2015-08-05 2015-08-06 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
PCT/EP2016/068727 WO2017021527A2 (fr) 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers

Publications (2)

Publication Number Publication Date
MA46022A true MA46022A (fr) 2019-07-03
MA46022B1 MA46022B1 (fr) 2021-03-31

Family

ID=54200350

Family Applications (4)

Application Number Title Priority Date Filing Date
MA053680A MA53680A (fr) 2015-08-05 2016-08-05 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA46022A MA46022B1 (fr) 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA41879A MA41879A1 (fr) 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA053452A MA53452A (fr) 2015-08-05 2016-08-05 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053680A MA53680A (fr) 2015-08-05 2016-08-05 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA41879A MA41879A1 (fr) 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA053452A MA53452A (fr) 2015-08-05 2016-08-05 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers

Country Status (35)

Country Link
US (23) US9908920B2 (fr)
EP (4) EP3331900B1 (fr)
JP (3) JP6884752B2 (fr)
KR (1) KR20180035845A (fr)
CN (2) CN107849107A (fr)
AR (1) AR105817A1 (fr)
AU (8) AU2016303021B2 (fr)
BR (1) BR112018001687A2 (fr)
CA (3) CA3110640A1 (fr)
CL (7) CL2018000324A1 (fr)
CO (1) CO2018002202A2 (fr)
CR (6) CR20200431A (fr)
CY (1) CY1123854T1 (fr)
DK (1) DK3331900T3 (fr)
EA (1) EA201890440A1 (fr)
ES (1) ES2862400T3 (fr)
GB (1) GB201513921D0 (fr)
HR (1) HRP20210709T8 (fr)
HU (1) HUE053657T2 (fr)
IL (2) IL310078A (fr)
LT (1) LT3331900T (fr)
MA (4) MA53680A (fr)
MD (1) MD3331900T2 (fr)
MX (2) MX2018001421A (fr)
PE (1) PE20180695A1 (fr)
PH (1) PH12018500189A1 (fr)
PL (1) PL3331900T3 (fr)
PT (1) PT3331900T (fr)
RS (1) RS61713B1 (fr)
SG (1) SG10202001660YA (fr)
SI (1) SI3331900T1 (fr)
TW (3) TW202106702A (fr)
UA (1) UA125816C2 (fr)
WO (1) WO2017021527A2 (fr)
ZA (1) ZA201800513B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2508923A (en) * 2012-12-17 2014-06-18 Bombardier Transp Gmbh Inductive power transfer system having inductive sensing array
MY191939A (en) 2013-08-05 2022-07-19 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer, including nsclc
ES2907629T3 (es) 2015-08-05 2022-04-25 Eisai R&D Man Co Ltd Un método para preparar un oligómero de fosforodiamidato sustancialmente puro diastereoisoméricamente, un oligómero de fosforodiamidato preparado mediante dicho método y una composición farmacéutica que comprende dicho oligómero de fosforodiamidato
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3389630B1 (fr) 2015-12-16 2023-11-08 Gritstone bio, Inc. Identification de néogènes, fabrication et utilisation
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
EP4317432A3 (fr) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH Récepteurs de lymphocytes t à appariement amélioré
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018213467A1 (fr) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies et procédés d'utilisation
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
CR20200013A (es) 2017-07-14 2020-03-11 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
EP3714275A4 (fr) 2017-11-22 2021-10-27 Gritstone bio, Inc. Réduction de la présentation d'épitope de jonction pour des néo-antigènes
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
MX2020008327A (es) 2018-02-09 2020-10-28 Immatics Us Inc Metodos para preparar celulas t.
WO2019232483A1 (fr) * 2018-06-01 2019-12-05 Geneoscopy, Llc Méthode de détection
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh) * 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
US20220127313A1 (en) * 2019-02-12 2022-04-28 Vanderbilt University Polypeptides for restoring endothelial function and methods of use thereof
WO2020191172A1 (fr) 2019-03-19 2020-09-24 Immatics US, Inc. Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation
AU2020283500A1 (en) 2019-05-27 2022-01-27 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
MX2021015033A (es) 2019-06-06 2022-01-18 Immatics Biotechnologies Gmbh Clasificacion con contraseleccion utilizando peptidos de secuencias similares.
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
BR112022016909A2 (pt) 2020-02-24 2022-12-06 Immatics Us Inc Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021207823A1 (fr) * 2020-04-14 2021-10-21 Université de Montréal Nouveaux antigènes spécifiques à une tumeur pour la leucémie myéloïde aiguë (aml) et leurs utilisations
WO2022040631A1 (fr) 2020-08-21 2022-02-24 Immatics US, Inc. Procédés d'isolement de lymphocytes t sélectionnés cd8+
EP4255474A1 (fr) * 2020-12-07 2023-10-11 Iogenetics, LLC. Immunothérapies personnalisées
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh BMA031 antigen-binding polypeptides
EP4113120A1 (fr) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Procédé de caractérisation des caractéristiques de liaison entre un peptide d'intérêt et des molécules du cmh
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
CN113527435B (zh) * 2021-07-14 2022-06-07 呈诺再生医学科技(珠海横琴新区)有限公司 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用
WO2023025851A1 (fr) 2021-08-24 2023-03-02 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1037656A (en) 1911-11-28 1912-09-03 Thomas F Loughran Prorating-weir.
US1178658A (en) 1914-06-11 1916-04-11 United Shoe Machinery Ab Gripper mechanism for pulling-over machines.
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2003040165A2 (fr) * 2000-10-19 2003-05-15 Epimmune Inc. Peptides de liaison hla de classe i et ii et leurs utilisations
WO2004031211A2 (fr) 2002-10-03 2004-04-15 Epimmune Inc. Peptides de liaison hla et utilisations de ces derniers
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
AU6359494A (en) * 1993-03-05 1994-09-26 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6824993B2 (en) * 1995-06-06 2004-11-30 Human Genome Sciences, Inc. Antibodies that bind human prostate specific G-protein receptor HPRAJ70
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
DE19623825C1 (de) 1996-06-14 1998-01-08 Rottefella As Langlauf- oder Tourenskibindung
WO1998010292A1 (fr) * 1996-09-06 1998-03-12 Centocor, Inc. Anticorps monoclonaux contre l'antigene prostatique specifique et procedes de detection de l'antigene prostatique specifique
US7008772B1 (en) * 1997-02-25 2006-03-07 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2001025272A2 (fr) 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
WO2001025446A1 (fr) * 1999-10-07 2001-04-12 Schering Aktiengesellschaft Adn codant le polypeptide prost 07
AU1656501A (en) * 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1261708A2 (fr) * 2000-01-14 2002-12-04 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
AU2001236589A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
US20030219806A1 (en) * 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001249549A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2316950A1 (fr) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production
WO2001074904A2 (fr) * 2000-03-31 2001-10-11 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour celles-ci
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
AU2001275246B2 (en) 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
DE60120712T2 (de) * 2000-08-11 2007-07-19 Mount Sinai Hospital, Toronto Kallikrein gen
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7459539B2 (en) * 2000-12-15 2008-12-02 Agensys, Inc. Antibody that binds zinc transporter protein 108P5H8
AU2002227445A1 (en) * 2000-12-18 2002-07-01 Curagen Corporation Proteins and nucleic acids encoding same
AUPR402201A0 (en) * 2001-03-27 2001-04-26 Queensland University Of Technology Polynucleotides and polypeptides linked to cancer and/or benign tumours
EP1499350A4 (fr) 2001-08-31 2006-02-08 Agensys Inc Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
DE10215321A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
EP2301972A1 (fr) * 2002-08-12 2011-03-30 The Council Of The Queensland Institute Of Medical Research Procédé pour la préparation de lipopeptides immunogènes comprenant des épitopes T-auxiliaires et de cellules B
US7906620B2 (en) * 2002-08-16 2011-03-15 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
EP1558643B1 (fr) 2002-11-09 2009-05-27 Immunocore Ltd. Presentation de recepteurs pour l'antigene des lymphocytes t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0318096D0 (en) * 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
US20050053988A1 (en) 2003-08-08 2005-03-10 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Gene expressed in breast cancer and methods of use
WO2006092175A1 (fr) * 2005-02-28 2006-09-08 Nycomed Gmbh Methode d'identification de modulateurs de pde11
DE602006014106D1 (de) * 2005-03-14 2010-06-17 Link Genomics Inc Verfahren zur diagnose von prostatakrebs
PT1806358E (pt) 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
WO2007053570A2 (fr) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Complexe polypeptidique de trpm8 et de calmoduline et tissus correspondants
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2300040A4 (fr) 2008-05-01 2012-06-27 Beth Israel Hospital Procédés et compositions pour immunothérapie du cancer de la prostate
NO2119726T3 (fr) 2008-05-14 2015-05-23
EP2337795A2 (fr) * 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2010102157A1 (fr) 2009-03-04 2010-09-10 The Regents Of The University Of California Prédicteurs moléculaires de la réponse biologique à un inhibiteur de cenpe dans un cancer
EP2550529B1 (fr) * 2010-03-23 2021-11-17 Iogenetics, LLC. Procédés bioinformatiques pour déterminer la liaison de peptides
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
CN103282384A (zh) * 2010-07-15 2013-09-04 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法
US20120121592A1 (en) * 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
CA2816225A1 (fr) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Anticorps qui se lient a des ligands de recepteurs de lymphocytes t solubles
SG191154A1 (en) * 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EP2771349B1 (fr) * 2011-09-16 2020-02-26 Iogenetics, LLC. Procédés bio-informatiques de détermination de liaisons peptidiques
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
WO2013151664A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines
WO2014047085A2 (fr) 2012-09-20 2014-03-27 Rongfu Wang Antigène de tumeur spécifique de la prostate et ses utilisations
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2808392A1 (fr) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer
TWI775117B (zh) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
WO2016138362A1 (fr) * 2015-02-26 2016-09-01 The Board Of Trustees Of The University Of Arkansas Vaccin de traitement pour le cancer de la prostate
EP3286361A4 (fr) * 2015-04-23 2019-05-08 Nantomics, LLC Néo-épitopes de cancer
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
SG11201911430PA (en) * 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
EP4259206A2 (fr) 2020-12-14 2023-10-18 BioNTech US Inc. Antigènes spécifiques de tissu pour une immunothérapie anticancéreuse

Also Published As

Publication number Publication date
US12076381B2 (en) 2024-09-03
JP2018529320A (ja) 2018-10-11
DK3331900T3 (da) 2021-03-29
IL310078A (en) 2024-03-01
US10238727B2 (en) 2019-03-26
US20220143162A1 (en) 2022-05-12
US20190054160A1 (en) 2019-02-21
LT3331900T (lt) 2021-03-25
RS61713B1 (sr) 2021-05-31
US20170305982A1 (en) 2017-10-26
CR20200433A (es) 2020-10-19
US11826409B2 (en) 2023-11-28
IL257331A (en) 2018-03-29
WO2017021527A3 (fr) 2017-04-27
AU2021202057A1 (en) 2021-04-29
US20210283230A1 (en) 2021-09-16
HRP20210709T8 (hr) 2022-03-18
CN114395013A (zh) 2022-04-26
AR105817A1 (es) 2017-11-15
US10500259B2 (en) 2019-12-10
CR20200435A (es) 2020-10-14
CA3110633A1 (fr) 2017-02-09
CA3110640A1 (fr) 2017-02-09
US20200000900A1 (en) 2020-01-02
CL2021001744A1 (es) 2022-02-11
CL2021001543A1 (es) 2022-01-21
CL2022003264A1 (es) 2023-02-24
MX2021015933A (es) 2022-02-03
EP4324472A3 (fr) 2024-08-28
US11786584B2 (en) 2023-10-17
SI3331900T1 (sl) 2021-08-31
US11058754B2 (en) 2021-07-13
CR20180074A (es) 2018-07-23
EP4324472A2 (fr) 2024-02-21
AU2021202060A1 (en) 2021-04-29
CL2018000324A1 (es) 2018-05-18
CO2018002202A2 (es) 2018-11-22
PT3331900T (pt) 2021-03-18
AU2021202058B2 (en) 2023-04-13
US9908920B2 (en) 2018-03-06
AU2021202059A1 (en) 2021-04-29
EP3854801A2 (fr) 2021-07-28
JP7142957B2 (ja) 2022-09-28
US20220143164A1 (en) 2022-05-12
US20170037089A1 (en) 2017-02-09
EA201890440A1 (ru) 2018-08-31
AU2021202060B2 (en) 2023-06-15
EP3331900B1 (fr) 2021-02-17
US20190275131A1 (en) 2019-09-12
US10799569B2 (en) 2020-10-13
US20220125902A1 (en) 2022-04-28
EP3842446A1 (fr) 2021-06-30
CA2994771A1 (fr) 2017-02-09
CR20200434A (es) 2020-10-19
WO2017021527A2 (fr) 2017-02-09
US11065315B2 (en) 2021-07-20
US20210275653A1 (en) 2021-09-09
PL3331900T3 (pl) 2021-08-09
US20200323969A1 (en) 2020-10-15
AU2021202059B2 (en) 2023-04-13
US20220152171A1 (en) 2022-05-19
AU2021202056A1 (en) 2021-04-29
CA2994771C (fr) 2021-04-20
MA53452A (fr) 2021-06-30
JP2022191218A (ja) 2022-12-27
AU2021202056B2 (en) 2023-04-06
UA125816C2 (uk) 2022-06-15
MA41879A1 (fr) 2019-05-31
US10532091B1 (en) 2020-01-14
US20220133870A1 (en) 2022-05-05
AU2016303021B2 (en) 2021-02-25
PE20180695A1 (es) 2018-04-23
MA53680A (fr) 2021-09-29
AU2023233214A1 (en) 2023-10-12
JP6884752B2 (ja) 2021-06-09
MA46022B1 (fr) 2021-03-31
US12097249B2 (en) 2024-09-24
US20190374626A1 (en) 2019-12-12
US10383930B2 (en) 2019-08-20
CY1123854T1 (el) 2022-05-27
US20170326215A1 (en) 2017-11-16
US20210275654A1 (en) 2021-09-09
CL2021001544A1 (es) 2022-01-21
US20200397878A1 (en) 2020-12-24
US9993539B2 (en) 2018-06-12
US10449238B2 (en) 2019-10-22
US10155032B2 (en) 2018-12-18
CN107849107A (zh) 2018-03-27
US20190091311A1 (en) 2019-03-28
KR20180035845A (ko) 2018-04-06
SG10202001660YA (en) 2020-04-29
US20240016908A1 (en) 2024-01-18
AU2023204661A1 (en) 2023-08-10
US20220143163A1 (en) 2022-05-12
CL2021001545A1 (es) 2022-01-21
GB201513921D0 (en) 2015-09-23
TW202106702A (zh) 2021-02-16
US20180344827A1 (en) 2018-12-06
AU2021202058A1 (en) 2021-04-29
MD3331900T2 (ro) 2021-05-31
US10478480B2 (en) 2019-11-19
EP3331900A2 (fr) 2018-06-13
TWI829618B (zh) 2024-01-21
US20220152175A1 (en) 2022-05-19
TW202415673A (zh) 2024-04-16
MX2018001421A (es) 2018-03-15
EP3854801A3 (fr) 2021-09-29
US12102670B2 (en) 2024-10-01
US10376568B2 (en) 2019-08-13
CR20200431A (es) 2020-10-14
HRP20210709T1 (hr) 2021-11-26
AU2016303021A1 (en) 2018-03-22
HUE053657T2 (hu) 2021-07-28
CR20200432A (es) 2020-10-19
CL2021001542A1 (es) 2022-01-21
TW201713682A (zh) 2017-04-16
AU2021202057B2 (en) 2023-04-13
US20190240305A1 (en) 2019-08-08
ES2862400T3 (es) 2021-10-07
ZA201800513B (en) 2018-12-19
PH12018500189A1 (en) 2018-07-30
BR112018001687A2 (pt) 2018-09-18
JP2021040639A (ja) 2021-03-18
US20180009858A9 (en) 2018-01-11
US20180127473A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MA46022A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA43327A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA44693B1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA42045A (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MA42294B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA43457A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA46648A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA44551A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
MA46508A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA43090A1 (fr) Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
MA42381A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MA43330A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA49158B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA47367B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA41664A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
MA46503A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA43596A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers